2.44
Inmune Bio Inc Aktie (INMB) Neueste Nachrichten
INmune Bio Inc (INMB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Inmune Bio stock steadies as investors await next data catalyst - AD HOC NEWS
INmune Bio undervalued as Ebstrocel for RDEB ne... - Pluang
INmune Bio: CORDStrom In The Lead After Signs Of UK Regulatory Alignment (NASDAQ:INMB) - Seeking Alpha
INMB Stock Gained 3% Today – What Did The FDA Say About Its Alzheimer’s Trial? - Stocktwits
aTyr Pharma And 2 Other Penny Stocks With Promising Potential - Sahm
INmune Bio submits EU regulatory filings for Ebstrocel in RDEB By Investing.com - Investing.com Canada
Inmune Bio Targets UK Maa In Q4 2026, EU Maa And US BLA In Q1 2027 - TradingView
INmune Bio (INMB) Climbs 4.33% to $2.17 as Traders Test Key Resistance at $2.28Low Volatility Picks - dars.gov.et
Inmune Stock Price Forecast. Should You Buy INMB? - StockInvest.us
INmune Bio Inc (INMB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
INmune Bio (INMB) Q2 2026 Earnings Call Transcript - AOL.com
INmune Bio Advances Ebstrocel Regulatory Filings and Clinical Plans - sekbernews.id
INmune Bio (NASDAQ:INMB) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Q2 2026 INmune Bio Inc Earnings Call Transcript - GuruFocus
Earnings call transcript: INmune Bio posts narrower Q2 2026 loss, eyes filings - Investing.com South Africa
INmune Bio, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
INmune Bio Inc (INMB) (Q2 2026) Earnings Call Highlights: Regula - GuruFocus
INmune Bio Inc (INMB) (Q2 2026) Earnings Call Highlights: Regulatory Wins and Strategic Focus ... - Yahoo Finance
INmune Bio Q2 Earnings Call Highlights - MarketBeat
INmune Bio Q2 2026 Earnings: Tax-Credit Benefit Narrows Net Loss - TradingKey
INmune Bio (NASDAQ:INMB) Releases Quarterly Earnings Results, Beats Expectations By $0.16 EPS - MarketBeat
INMB: Ebstrocel nears global filings as financials strengthen and XPro advances in Alzheimer's - TradingView
INmune Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress - The Manila Times
Inmune Bio, Inc. Q2 2026: Revenue $0 Net loss $(1.27)M, EPS $(0.05) — 10-Q Summary - TradingView
INmune Bio Q2 net loss narrows on lower impairment charges - TradingView
INmune Bio (NASDAQ: INMB) posts $6.7M loss and warns on cash runway - Stock Titan
10-Q: INmune Bio | 10-Q: Q2 2026 Earnings Report - Moomoo
INmune Bio Inc expected to post a loss of 21 cents a shareEarnings Preview - TradingView
INmune Bio receives $4.6M in R&D rebates from Australia, UK - Investing.com UK
INmune Bio Strengthens Cash Runway With R&D Rebates - TipRanks
INmune Bio receives ~$4.6M in R&D rebates, cash proceeds exceed Q2 operating cash use - TradingView
INmune Bio (INMB.US) will release its earnings report after market close on August 6. - moomoo.com
INmune Bio Inc.Common stock (INMB) Stock Price, News, Quote & History - FinancialContent
INmune Bio Receives $4.2 Million Australia R&D Rebate, Extending Cash Runway for CORDStrom Development - Quiver Quantitative
INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on ... - Caledonian Record
INmune Bio schedules Aug. 6 webcast on second-quarter results - Stock Titan
INmune Bio forms scientific advisory board for cell therapy By Investing.com - Investing.com Nigeria
INMB Q2'26 Earnings: revenue estimate is 0 USD - TradingView
INMB|INmune Bio Inc|Price:1.745|Chg%:+0.125 - TradingKey
INmune Bio Inc. (INMB) Holds Steady at $1.73 as Traders Eye Defined Trading RangeVOLD Alert - vinanet.vn
INmune Bio Inc (INMB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
INmune Bio Inc (INMB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
INmune Bio Inc (INMB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
INMB|INmune Bio Inc|Price:2.330|Chg%:-0.070 - TradingKey
INmune Bio Inc (INMB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
INmune Bio Inc (INMB) Valuation: PE, PB & Fair Value Analysis - TradingKey
TradingKey - TradingKey
INMB|INmune Bio Inc|Price:1.620|Chg%:-0.100 - TradingKey
INmune Bio Inc (INMB) Institutional Confidence - TradingKey
INmune Bio (INMB) Slides 4% Amidst Subdued Trading, Testing Support at $1.57Bollinger Walk - dars.gov.et
INmune Bio (INMB) Slides 6.5% as Selling Pressure Mounts, Tests Key Support at $1.63Investment Factor - dars.gov.et
Inmune Bio stock trades on Nasdaq as investors watch trial progress and cash runway - Ad-hoc-news.de
INMB Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline Amid No RevenueMargin Compression Risk - vinanet.vn
INMB Achieves Breakthrough in Umbilical Cord Tissue Processing - GuruFocus
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):